Application for Paxlovid – Swissmedic approves drugs on Covid 19 for two years
– Swissmedic approves drugs on Covid 19 for two years
Paxlovid has been approved in Switzerland for a limited period. The drug is used to treat adult patients at increased risk of severe Covid 19.
The Swissmedic Institute for Therapeutic Products has approved Covid 19 Paxlovid for a limited period of two years. Two tablets with two active substances could already be prescribed. They are intended for adult patients with Covid-19.
The manufacturer is the American pharmaceutical company Pfizer, as announced by Swissmedic on Wednesday. The institute checked the application for approval in an ongoing evaluation, in which Pfizer continuously collected and transmitted the necessary data.
Paxlovid is used in adult patients who do not need supplemental oxygen or a hospital stay, but are at increased risk of developing a severe course of Covid-19. Treatment should begin as soon as possible after diagnosis and within five days of onset of symptoms. It takes five days.
Combination of two active substances
Paxlovid consists of two active substances, nirmatrelvir and ritonavir, which are given in two tablets. They have an antiviral effect. According to Swissmedic, nirmatrelvir is a new active substance that inhibits the enzyme in coronavirus, which is important for its reproduction.
Ritonavir is added to break down less rapidly nirmatrelvir in the liver and to persist its antiviral effect. Ritonavir has been used in the treatment of HIV for more than 20 years.
Pfizer did not provide any data on its efficacy against omicron variants of the virus, as Swissmedic further wrote. However, laboratory data suggest that Paxlovid acts against omicron variants in a test tube.
With Paxlovid, six Covid 19 drugs are approved in Switzerland for a limited or unlimited period.